Synaptogenix Inc (SNPX)

[SF Wolf]

We reckless abandon I will take a stab at answering your question blu 1.

You write “Assuming bryostatin-1 becomes the new SOC and does indeed reverse Alzheimers Disease, ballpark, what would share price of NTRP eventually be?”

I believe the first question to ask is how much of a run-up in share price will there be as we approach the April P2b data release.

Both Dr. Alkon, President and Chief Scientific Officer, and Dr. Wilke, CEO, have made very positive statements at investor conferences and in the Benzinga articles in the last two weeks. So there are positive expectations among what is still a very small group of stockholders (maybe 500 or so).

Publicity about NTRP has been limited and within the on-line investor community. Bloomberg, Rueters, and the mainstream media have not picked-up on it yet.

The other side of the equation is that the P2b study is taking place at 29 locations. Anecdotal leaks from the researchers, staff, family member of the participants, etc. are a possibility and could affect the share price.
SEE: A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease https://clinicaltrials.gov/ct2/show/NCT02431468?term=Bryostatin-1&rank=8

Personally, I am watching trading volume, chart metrics, twitter posts, and company info.

I believe that lacking negative reports or positive rumors, the stock price could move up to the $35 to $50 range just prior to the data release…just my opinion.

Then if the data is as positive as the company is implying all bets are off and the sky is the limit.